Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes

Pharmacokinetic profiles of single- and multiple-dose regimens of repaglini de were evaluated in 12 elderly subjects with type 2 diabetes. On day 1, fo llowing a 10-hour fast, subjects received a single 2-mg dose of repaglinide . Starting on day 2 and continuing for 7 days, each subject received a 2-mg dose of repaglinide 15 minutes before each of the three main meals. On day 9, subjects received a single 2-mg dose of repaglinide. Pharmacokinetic pr ofiles, including area under the curve (AUC), log(AUC), maximal concentrati on (C-max), log(C-max), time to maximal concentration (T-max), and half-lif e (T-1/2), were determined at completion of the single- and multiple-dose r egimens (days 1 and 9, respectively). Trough repaglinide values were collec ted on days 2 through 7. The mean log(AUC) values after multiple dosing wer e significantly higher than the values obtained after a single dose. The me an values for log(C-max), and T-max were comparable after each dosing regim en. The T-1/2 of repaglinide after multiple dosing was 1.7 hours. The troug h values for repaglinide were low. No hypoglycemic events were reported. Th e pharmacokinetic profiles of repaglinide after single- and multiple-dose r egimens were similar, and repaglinide was well tolerated by elderly subject s with type 2 diabetes.